These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29801053)

  • 81. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Sense in antisense therapy for spinal muscular atrophy.
    MacKenzie A
    N Engl J Med; 2012 Feb; 366(8):761-3. PubMed ID: 22356331
    [No Abstract]   [Full Text] [Related]  

  • 83. Willingness to Pay for a Newborn Screening Test for Spinal Muscular Atrophy.
    Lin PJ; Yeh WS; Neumann PJ
    Pediatr Neurol; 2017 Jan; 66():69-75. PubMed ID: 27769729
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Evaluator Training and Reliability for SMA Global Nusinersen Trials1.
    Glanzman AM; Mazzone ES; Young SD; Gee R; Rose K; Mayhew A; Nelson L; Yun C; Alexander K; Darras BT; Zolkipli-Cunningham Z; Tennekoon G; Day JW; Finkel RS; Mercuri E; De Vivo DC; Baldwin R; Bishop KM; Montes J
    J Neuromuscul Dis; 2018; 5(2):159-166. PubMed ID: 29865090
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Deletion and conversion in spinal muscular atrophy patients: is there a relationship to severity?
    DiDonato CJ; Ingraham SE; Mendell JR; Prior TW; Lenard S; Moxley RT; Florence J; Burghes AH
    Ann Neurol; 1997 Feb; 41(2):230-7. PubMed ID: 9029072
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam-Part 2: Experience from a nusinersen clinical study.
    Bishop KM; Montes J; Finkel RS
    Muscle Nerve; 2018 Jan; 57(1):142-146. PubMed ID: 28556387
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Natural history data in adults with SMA.
    Vázquez-Costa JF
    Lancet Neurol; 2020 Jul; 19(7):564-565. PubMed ID: 32562673
    [No Abstract]   [Full Text] [Related]  

  • 88. Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function.
    Pane M; Palermo C; Messina S; Sansone VA; Bruno C; Catteruccia M; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Brigati G; de Sanctis R; Coratti G; Lucibello S; Bertini E; Vita G; Tiziano FD; Mercuri E;
    Neuromuscul Disord; 2018 Jul; 28(7):582-585. PubMed ID: 29960818
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Nusinersen: A Treatment for Spinal Muscular Atrophy.
    Claborn MK; Stevens DL; Walker CK; Gildon BL
    Ann Pharmacother; 2019 Jan; 53(1):61-69. PubMed ID: 30008228
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
    Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
    Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2018 Jul; 32(7):689-696. PubMed ID: 30027400
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
    Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
    Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center.
    La Foresta S; Faraone C; Sframeli M; Vita GL; Russo M; Profazio C; Rulli I; Gitto E; Versaci A; Messina S; Vita G
    Neurol Sci; 2018 Nov; 39(11):1961-1964. PubMed ID: 30043247
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.
    Biliouris K; Gaitonde P; Yin W; Norris DA; Wang Y; Henry S; Fey R; Nestorov I; Schmidt S; Rogge M; Lesko LJ; Trame MN
    CPT Pharmacometrics Syst Pharmacol; 2018 Sep; 7(9):581-592. PubMed ID: 30043511
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Evidence in focus: Nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Michelson D; Ciafaloni E; Ashwal S; Lewis E; Narayanaswami P; Oskoui M; Armstrong MJ
    Neurology; 2018 Nov; 91(20):923-933. PubMed ID: 30315070
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps.
    Gidaro T; Servais L
    Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Ambulatory function in spinal muscular atrophy: Age-related patterns of progression.
    Montes J; McDermott MP; Mirek E; Mazzone ES; Main M; Glanzman AM; Duong T; Young SD; Salazar R; Pasternak A; Gee R; De Sanctis R; Coratti G; Forcina N; Fanelli L; Ramsey D; Milev E; Civitello M; Pane M; Pera MC; Scoto M; Day JW; Tennekoon G; Finkel RS; Darras BT; Muntoni F; De Vivo DC; Mercuri E
    PLoS One; 2018; 13(6):e0199657. PubMed ID: 29944707
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care.
    Sansone VA; Albamonte E; Salmin F; Casiraghi J; Pirola A; Bettinelli M; Rao F; Mancini L; Tovaglieri N; Fedeli F; Stoia P; Heinen M; Cozzi V; Carraro E; Lunetta C; Di Bari A; Mercuri E;
    Neurol Sci; 2019 Feb; 40(2):327-332. PubMed ID: 30430317
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Changing respiratory expectations with the new disease trajectory of nusinersen treated spinal muscular atrophy [SMA] type 1.
    Fitzgerald DA; Doumit M; Abel F
    Paediatr Respir Rev; 2018 Sep; 28():11-17. PubMed ID: 30414815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.